Pediatrix Medical Group (MD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.63
- Estimate
- $0.59
- Surprise
- +6.6%
- Revenue (period 2026-06-30)
- $487.8M
- Score at report (before → after)
- 6.0 → 6.0/10
Revenue source: xbrl.
How the report landed
Pediatrix Medical Group (MD) beat the $0.59 estimate with adjusted EPS of $0.63 — a clear 6.6% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.0/10) to Hold at 6.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MD Sell at 5.5/10.
3 of the last 4 quarters beat the estimate; this quarter's +6.6% surprise compares with a +14.9% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
- Earnings estimates trending DOWN
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $25.86
- Price target
- $27.01
- Stop
- $24.42
- Upside to target
- +4.4%
At 12.6× trailing and 10.8× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
MD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $2.14B
- P/E (fwd)
- 10.8
- P/E (ttm)
- 12.6
- 52-week range
- $15.70–$27.94
- Off 52-week high
- 7.4%
- RSI (14)
- 38
- Volume vs avg
- 0.62×
- Score today
- 5.5/10